New Horizons in Myelodysplastic Syndrome (MDS): Diagnosis, Risk Stratification, and Novel Therapies - Episode 2: Relating the Pathophysiology of MDS to the Mechanism of Action (MOA) of Novel Agents

Release Date: May 31, 2021
Last Reviewed: May 26, 2021
Expiration Date: May 31, 2022
Time to Complete Activity:  0.50 hours

*This activity expired for credit on May 31, 2022 and is no longer available for credit

Daniel Pollyea, MD, MS (Chair)

Associate Professor
University of Colorado School of Medicine
Clinical Director of Leukemia Services
Robert H. Allen, MD Endowed Chair in Hematology Research
Aurora, CO

Amy DeZern, MD, MHS
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Director, Bone Marrow Failure and MDS Program
Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Baltimore, MD

David Sallman, MD
Assistant Member of the Malignant Hematology Department
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

This activity is jointly provided by Paradigm Medical Communications, LLC and Educational Review Systems, Inc. 
In collaboration with the MDS Foundation, Inc. 

Disclosure of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.    

Target Audience
This activity has been designed to address the educational needs of hematology/oncology physicians, pathologists, pharmacists, oncology advanced practitioners, oncology nurses, and other healthcare professionals involved in the treatment of patients with MDS.

Statement of Need
MDS is a hematologic malignancy affecting the hematopoietic stem cells, primarily in older individuals. The disease course is heterogeneous and varies based on the underlying pathophysiology of the disease. Diagnosis can be challenging, with some patients waiting years before obtaining a correct diagnosis. Because the disease course can also vary among patients, risk stratification is critical for selecting the optimal treatment regimen. Historically, there have been few effective treatment options for MDS, creating a critical unmet need for therapies that improve quality of life and potentially prolong life. In 2020, several new agents received US Food and Drug Administration (FDA) approval, representing the first new approvals for MDS in the last 14 years. More novel emerging agents are on the horizon, pointing to a paradigm shift in in MDS treatment coming in the near future. The 3 episodes in this
MDS Prime TimeTM series will address diagnosis, risk stratification, and the mechanisms and clinical applications of new and emerging agents in MDS.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review the MOAs of new and novel emerging therapies as they relate to the pathophysiology of MDS

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Paradigm Medical Communications, LLC and Educational Review Systems, Inc. Paradigm Medical Communications, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Education
Educational Review Systems, Inc is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 0.5 hour of continuing nursing education.

Educational Review Systems, Inc is also approved for nursing continuing education by the state of California, the state of Florida, and the District of Columbia.

Pharmacist Accreditation and Designation Statement
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for .50 contact hours (0.5 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days. 

UAN # 0761-9999-21-053-H01-P 

This is a knowledge-based activity. 

PA Continuing Education
PAs may claim a maximum of 0.50 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. 

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Instructions for Participation 
To receive a CME certificate of participation, you should:

  • Follow instructions to register or log in with your professional information and complete the preactivity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or

There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here:

Technical Support: If you have any technical problems or playback issues email us at

In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been resolved.

Daniel Pollyea, MS, MS
Consulting Fees: AbbVie Inc.; Aprea Therapeutics, Inc; Astellas Pharma US, Inc; Bristol-Myers Squibb Company; Celgene Corporation; Foghorn Therapeutics; Genentech, Inc; Gilead Sciences, Inc; Karyopharm Therapeutics; Kiadis Pharma; Novartis; Syndax; Syros Pharmaceuticals, Inc; Takeda Pharmaceutical Company Ltd
Grant/Research Support: AbbVie Inc.

Amy DeZern, MD, MHS
Consulting Fees: Aprea Therapeutics, Inc; Novartis

Dave Sallman, MD
Consulting Fees: AbbVie Inc.; Agios, Inc; Aprea Therapeutics, Inc; Bristol-Myers Squibb Company; Celyad Oncology; Gilead Sciences, Inc; Intellia Therapeutics, Inc; Kite; Magenta Health; Novartis; Shattuck Labs, Inc; Syndax
Speakers Bureau: Agios Inc; Bristol-Myers Squibb Company; InCyte Corporation
Grant/Research Support: Celgene Corporation; Jazz Pharmaceuticals, Inc.

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Educational Review Systems, Inc staff members have no financial relationships to disclose.

Independent peer reviewer, Bernard M. Abrams, MD, has no financial relationships to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at

© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.